# o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

> **NCT07333976** · PHASE2 · COMPLETED · sponsor: **Tri-Service General Hospital** · enrollment: 90 (actual)

## Conditions studied

- Prostate Cancer Metastatic Disease
- Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Neurotoxicity

## Interventions

- **DRUG:** Tadalafil 5 mg

## Key facts

- **NCT ID:** NCT07333976
- **Lead sponsor:** Tri-Service General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-05
- **Primary completion:** 2023-12-22
- **Final completion:** 2024-08-13
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333976, "o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07333976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*